BofA reaffirmed Argenx and Vertex as top large‑cap biotech picks for 2026 with price targets of $1,013 and $598 respectively.
Argenx’s Vvygart shows strong sales in generalized myasthenia gravis and CIDP, with phase‑3 data for efgartigimod and empasiprubart expected Q3/Q4.
Vertex’s cystic fibrosis franchise fuels cash flow, while its rare‑kidney disease pipeline, highlighted by povetacicept data in IgA nephropathy, drives long‑term growth.
BofA also named small‑cap picks KalVista ($32), Rhythm ($149), Ocular Therapeutix ($27) and Bicara ($35), citing recent approvals for Ekterly and Imcivree.